Chagas' disease

New England Journal of Medicine

Volumn 373, Issue 5, 2015, Pages 456-466

  Bern, Caryn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NIFURTIMOX; POSACONAZOLE; RAVUCONAZOLE;

ABDOMINAL DISCOMFORT; ANOREXIA; ATRIOVENTRICULAR BLOCK; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CHAGAS DISEASE; CLINICAL FEATURE; DEFIBRILLATOR; DERMATITIS; DIET THERAPY; DISEASE COURSE; DISORIENTATION; DIZZINESS; EPIDEMIOLOGICAL DATA; ERYTHRODERMA; FEVER; FOOD CONTAMINATION; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HOST PARASITE INTERACTION; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY DIAGNOSIS; LEUKOPENIA; LYMPHADENOPATHY; MEMORY DISORDER; MOOD CHANGE; MULTICENTER STUDY (TOPIC); MYALGIA; MYOTOMY; NAUSEA; NEURITIS; NEUROLOGIC DISEASE; NONHUMAN; PARASITE EXAMINATION; PARASITE TRANSMISSION; PARASITE VECTOR; PARASITEMIA; PARESTHESIA; PATHOGENESIS; POLYMERASE CHAIN REACTION; POLYNEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROTIST LIFE CYCLE STAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEROLOGY; SINUS NODE DISEASE; SKIN ALLERGY; SKIN DISEASE; THROMBOCYTOPENIA; TREMOR; TRYPANOSOMA CRUZI; VERTIGO; VOMITING; WATER CONTAMINATION; WEIGHT REDUCTION; COMPLICATION; GROWTH, DEVELOPMENT AND AGING; LIFE CYCLE STAGE;

CHAGAS DISEASE; HUMANS; LIFE CYCLE STAGES; PREVALENCE; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84938312688     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1410150     Document Type: Review

References (77)

1. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011;364:2527-34.
2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
3. Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012;54:845-52.
4. Rassi A Jr, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 2012;26:275-91.
5. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015;90:33-43.
6. Feliciangeli MD, Campbell-Lendrum D, Martinez C, Gonzalez D, Coleman P, Davies C. Chagas disease control in Venezuela: lessons for the Andean region and beyond. Trends Parasitol 2003;19:44-9.
7. Nouvellet P, Dumonteil E, Gourbière S. The improbable transmission of Trypanosoma cruzi to human: the missing link in the dynamics and control of Chagas disease. PLoS Negl Trop Dis 2013;7(11):e2505.
8. Samuels AM, Clark EH, Galdos-Cardenas G, et al. Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco. PLoS Negl Trop Dis 2013;7(8):e2358.
9. Maguire JH, Mott KE, Lehman JS, et al. Relationship of electrocardiographic abnormalities and seropositivity to Trypanosoma cruzi within a rural community in northeast Brazil. Am Heart J 1983;105:287-94.
10. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49(5):e52-e54.
11. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115:22-7.
12. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol 2006;22:583-8.
13. Hashimoto K, Schofield CJ. Elimination of Rhodnius prolixus in Central America. Parasit Vectors 2012;5:45.
14. Global burden of disease estimates for 2000-2012. Geneva:World Health Organization, 2014 (http://www.who.int/healthinfo/global-burden-disease/estimates/en/index2.html).
15. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 2011;24:655-81.
16. Cantey PT, Stramer SL, Townsend RL, et al. The United States Trypanosoma cruzi Infection Study: evidence for vectorborne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 2012;52:1922-30.
17. Garcia MN, Aguilar D, Gorchakov R, et al. Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg 2015;92:325-30.
18. Kapelusznik L, Varela D, Montgomery SP, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis 2013;57(1):e7.
19. Edwards MS, Rench MA, Todd CW, et al. Perinatal screening for Chagas disease in southern Texas. J Pediatr Infect Dis Soc 2015;4:67-70.
20. Stimpert KK, Montgomery SP. Physician awareness of Chagas disease, USA. Emerg Infect Dis 2010;16:871-2.
21. Verani JR, Montgomery SP, Schulkin J, Anderson B, Jones JL. Survey of obstetrician-gynecologists in the United States about Chagas disease. Am J Trop Med Hyg 2010;83:891-5.
22. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81.
23. Bern C, Martin DL, Gilman RH. Acute and congenital Chagas disease. Adv Parasitol 2011;75:19-47.
24. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009;95:524-34.
25. Acquatella H. Echocardiography in Chagas heart disease. Circulation 2007;115:1124-31.
26. Sabino EC, Ribeiro AL, Salemi VM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation 2013;127:1105-15.
27. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-23.
28. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001;31:550-4.
29. Dutra WO, Menezes CA, Magalhães LM, Gollob KJ. Immunoregulatory networks in human Chagas disease. Parasite Immunol 2014;36:377-87.
30. Tarleton RL. Chagas disease: a role for autoimmunity? Trends Parasitol 2003;19:447-51.
31. Machado FS, Dutra WO, Esper L, et al. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol 2012;34:753-70.
32. Pinto Dias JC. Natural history of Chagas disease. Arq Bras Cardiol 1995;65:359-66. (In Portuguese.)
33. Bustamante JM, Rivarola HW, Fernández AR, et al. Trypanosoma cruzi reinfections in mice determine the severity of cardiac damage. Int J Parasitol 2002;32:889-96.
34. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998;93:884-9.
35. Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010;33:191-200.
36. Miles MA, Cedillos RA, Póvoa MM, de Souza AA, Prata A, Macedo V. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1981;1:1338-40.
37. del Puerto R, Nishizawa JE, Kikuchi M, et al. Lineage analysis of circulating Trypanosoma cruzi parasites and their association with clinical forms of Chagas disease in Bolivia. PLoS Negl Trop Dis 2010;4(5):e687.
38. Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011. Am J Transplant 2013;13:2418-25.
39. Bacal F, Silva CP, Pires PV, et al. Transplantation for Chagas' disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transplant 2010;24(2):E29-E34.
40. Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007;101:31-50.
41. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg 2001;71:1833-8.
42. Kransdorf EP, Czer LS, Luthringer DJ, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant 2013;13:3262-8.
43. Fiorelli AI, Stolf NA, Honorato R, et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc 2005;37:2793-8.
44. Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant 2011;11:672-80.
45. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas Disease - grim outlook or glimmer of hope? PLoS Med 2007;4(12):e332.
46. Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011;5(1):e931.
47. Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 2009;3(4):e419.
48. Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007;7:1633-40.
49. Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014;370:1899-908.
50. Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen 2015;20:22-35.
51. Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010;54:4896-9.
52. Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 1997;30:139-44. (In Portuguese.)
53. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-34.
54. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009;64:1139-47.
55. Tornheim JA, Lozano Beltran DF, Gilman RH, et al. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 2013;7(9):e2407.
56. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 2010;51(10):e69-e75.
57. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection: preliminary report. Arzneimittelforschung 1972;22:1635-41.
58. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phse III, non-inferiority trial Lancet 2009;374:56-64.
59. Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma J Pediatr Hematol Oncol 2011;33:25-30.
60. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407-13.
61. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998;59:526-9.
62. Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014;8(5):e2907.
63. Cancado JR, Brener Z. Terapeutica. In:Brener Z, Andrade Z, eds. Trypanosoma cruzi e doença de Chagas. Rio de Janeiro:Guanabara Koogan, 1979:362-424.
64. Andrade AL, Martelli CM, Oliveira RM, et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 2004;71:594-7.
65. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 2004;37:365-75. (In Portuguese.)
66. Gascón J, Albajar P, Cañas E, et al. Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev Esp Cardiol 2007;60:285-93. (In Spanish.)
67. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006;19:583-7.
68. Viotti R, Alarcón de Noya B, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother 2014;58:635-9.
69. Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2014;5:CD003463.
70. Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009;104:Suppl 1:319-24.
71. Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 2014;8(11):e3312.
72. Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 2014;12:479-96.
73. Requena-Méndez A, López MC, Angheben A, et al. Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. Expert Rev Anti Infect Ther 2013;11:957-76.
74. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol 2012;9:576-89.
75. Gali WL, Sarabanda AV, Baggio JM, et al. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. Europace 2014;16:674-80.
76. Gürtler RE, Kitron U, Cecere MC, Segura EL, Cohen JE. Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci U S A 2007;104:16194-9.
77. Dias JC. Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz 2009;104:Suppl 1:41-5.